Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period

  • Auton Neurosci. 2019 May;218:51-53. doi: 10.1016/j.autneu.2019.02.004.
Mark Evans  1 ,  Mark Butt  2 ,  Patrice Belanger  3 ,  Thomas Cummings  4 ,  Jessica-Lyn Gremminger  4 ,  Mark Zorbas  1
Affiliations
  • 1. Pfizer Inc., San Diego, CA 92121, United States of America.
  • 2. Tox Path Specialists, LLC, Frederick, MD 21701, United States of America.
  • 3. Pfizer Inc., San Diego, CA 92121, United States of America. Electronic address: [email protected].
  • 4. Pfizer, Inc., Groton, CT 06340, United States of America.
PMID: 30890348 DOI: 10.1016/j.autneu.2019.02.004
Abstract

Tanezumab, a humanized monoclonal anti-NGF antibody, has demonstrated efficacy and safety profiles in Phase III clinical trials of chronic pain. In a 24-week study in non-human primates, morphological observations of sympathetic ganglia showed decreased ganglia volume, decreased neuronal size, and increased glial cell density compared with controls after 3 tanezumab treatments. Using stereological techniques to quantify glial cells, the present 26-week study found no significant difference after weekly treatments in total cervicothoracic ganglia satellite glial cell number between placebo- or tanezumab-treated cynomolgus monkeys. These findings suggest that tanezumab treatment does not result in a true gliosis in sympathetic ganglia.

Products